Mortality rates per lifecycle stage [28]. by Albertus Constantijn Sloof (20405090)

“…</p><p>Conclusions</p><p>The findings highlight the critical role of timely vaccination interventions in outbreak settings, demonstrating that even modest coverage levels can markedly decrease the spread of CHIKV. This study underscores the importance of preparedness, early detection and adaptive response capabilities to manage emerging infectious diseases in urban centres, advocating for strategic vaccine stockpiling and rapid deployment mechanisms to enhance public health outcomes.…”

Repetitive stress induces a decrease in sound-evoked activity. by Ghattas Bisharat (20706928)

“…<p>(a) Left: noise-evoked activity rates at different noise intensities for chronically tracked PPys cells in baseline and repeated stress conditions (<i>N</i> = 5 mice, <i>n</i> = 285 neurons, mean ± SE). …”

(A) Auxiliary marking points to ensure complete and accurate seating of the prosthesis. by Long Li (6555)

Changes in mortality and DALYs per100,000 rates by cancer types from 1990 to 2019 in Iran; a) Mortality rate; b) DALYs per100000 rate. by Mitra Darbandi (17967619)

Subjects:

Distribution of age-standardized total cancer in the provinces of Iran, 1990 and 2019. a) Mortality rate in 1990; b) Mortality rate in 2019; c) DALY rate in 1990; d) DALY rate in 2... by Mitra Darbandi (17967619)

Subjects:

Birth rate and population. by Jennifer Astley (19859612)

Subjects:

Cinacalcet administered early in the inactive phase markedly decrease parathyroid Ki-67 index. by Søren Egstrand (10906087)

Changes in the monthly contamination rate (per set) in blood culture (BC). by Miki Doi (15347878)

Ranking of age-standardized mortality rates and DALY in each province of Iran for cancers, 2019. a) Mortality rate; b) DALY. by Mitra Darbandi (17967619)

Subjects:

The age-standardized trends of all cancers in Iran. a) The Mortality Rate; b) DALYs per100000 rate between 1990 and 2019 in Iran. by Mitra Darbandi (17967619)

Subjects:

A. Quality of evidence: TOTVA vs. COT. B. Quality of evidence: TOTVA vs. NTET (including robotic approaches). by Huixia Ren (500186)

Subjects:

National (A) Medicare prescription rates per thousand Part D enrollees and (B) Medicare spending for clozapine gradually decreased for 2015-2020. by Luke R. Cavanah (19022435)

“…<p>National (A) Medicare prescription rates per thousand Part D enrollees and (B) Medicare spending for clozapine gradually decreased for 2015-2020.…”

Average annual percent change (AAPC) with 95% confidence interval (CI) in age standardized hepatocellular carcinoma incidence rates per 100,000, overall and by hepatitis B virus (H... by Joy Jiang (5483006)

Crude and age-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Crude and type-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Crude and residence-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Comparison of the albendazole and ivermectin parasitological cure rate (Per-protocol). by Luccheri Ndong Akomezoghe (18585684)

Difference between estimated taxonomic effort and actual number of species described per period and per family. Abbreviations: Increased = I; Stable = S; Decreased = D. by Janaína Gomes-da-Silva (7852157)

Percent of change for mortality and DALYs per100000 rates by cancers in Iran (1990 to 2019). by Mitra Darbandi (17967619)

Subjects:

The crude incidence rates of NPC and ENKTL. by Shyh-An Yeh (10011348)

Subjects: